You are here

Share:

Search Technologies

Showing 41-44 of 44 results found

Nanobodies Neutralizing Lassa Virus

The National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus as a possible treatment of Lassa virus infections.

T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a T-cell receptor (TCR) that confers high-avidity recognition of the HPV-specific oncoprotein E7. The TCR may be used in an adoptive cell therapy approach utilizing genetically engineered lymphocytes to treat HPV-positive malignancies.

T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a T-cell receptor (TCR) that confers high-avidity recognition of the HPV-specific oncoprotein E6. The TCR may be used in an adoptive cell therapy approach utilizing genetically engineered lymphocytes to treat HPV-positive malignancies.

Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein

Scientists at the National Cancer Institute (NCI) isolated a panel of single domain antibodies (known as ‘nanobodies’), targeting the S2 subunit of the spike protein of SARS-CoV-2 virus. These nanobodies bind to a highly conserved region in the S2 subunit of the spike protein, suggesting the potential to treat current and future SARS-CoV infections. The NCI seeks parties interested in collaborative research and/or licensing to further develop these nanobodies as a possible treatment of COVID-19 infections.

Pages